We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo's (MASI) iSirona to Boost Hospital Automation Platform
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) recently introduced iSirona, a compact, versatile medical device connectivity hub globally. The iSirona hub has been developed to maximize interoperability across continuum of care, with the capability of connecting up to six medical devices and automatically routing the data to the Hospital Automation platform.
For investor’s note, Masimo Hospital Automation platform is a customizable, versatile, and future-focused connectivity solution that ensures interoperability and secure flow of data throughout hospital systems.
With the launch of iSirona, Masimo is likely to strengthen its product portfolio.
More on the News
On the back of the robust and compact design, iSirona is capable of connecting multiple patient monitors, anesthesia machines, pumps and other medical devices in operating rooms and ICUs, where there is lack of space. Notably, iSirona – the newest member of the Hospital Automation platform – enables easy and fast connectivity wherever necessary by delivering offline data online and simplifying workflow to help clinicians boost patient care.
In fact, Masimo Root, a multimodal patient monitoring and connectivity platform, augmented by iSirona, aids in keeping accurate record of all patient data and presenting it to clinicians in the most suitable ways.
Industry Prospects
Per a report by Fortune Business insights, the global medical device market size was valued at $425.5 billion and is expected to reach $612.7 billion by 2025, at a CAGR of 5.4%. Technological advancement and rising demand for innovative therapies to overcome unmet healthcare needs are driving this market.
Notable Developments
In December 2020, Masimo announced that it is lending support to Renown Health by helping clinicians to address the COVID-19 surge through use of Masimo SafetyNet. Masimo SafetyNet is being utilized to provide care for COVID-19 infected patients to recover in the safety of their homes.
In November 2020, Masimo announced the receipt of CE mark for its Radius VSM, a wearable, tetherless vital signs monitor, and has been released in limited European markets. It offers a wide variety of physiological measurements, including continuous SET pulse oximetry, non-invasive blood pressure, body temperature, respiration rate, and electrocardiography.
Price Performance
Shares of the company have gained 50.3% in a year’s time compared with the industry’s growth of 22.1%.
Zacks Rank and Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space include Cantel medical Corp. , Hologic, Inc. (HOLX - Free Report) and Delcath Systems, Inc. (DCTH - Free Report) . While Cantel Medical and Hologic sport a Zacks Rank #1 (Strong Buy), Delcath Systems carries a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Cantel Medical has an estimated long-term earnings growth rate of 19%.
Hologic has an estimated long-term earnings growth rate of 17%.
Delcath Systems has a projected long-term earnings growth rate of 69%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Masimo's (MASI) iSirona to Boost Hospital Automation Platform
Masimo Corporation (MASI - Free Report) recently introduced iSirona, a compact, versatile medical device connectivity hub globally. The iSirona hub has been developed to maximize interoperability across continuum of care, with the capability of connecting up to six medical devices and automatically routing the data to the Hospital Automation platform.
For investor’s note, Masimo Hospital Automation platform is a customizable, versatile, and future-focused connectivity solution that ensures interoperability and secure flow of data throughout hospital systems.
With the launch of iSirona, Masimo is likely to strengthen its product portfolio.
More on the News
On the back of the robust and compact design, iSirona is capable of connecting multiple patient monitors, anesthesia machines, pumps and other medical devices in operating rooms and ICUs, where there is lack of space. Notably, iSirona – the newest member of the Hospital Automation platform – enables easy and fast connectivity wherever necessary by delivering offline data online and simplifying workflow to help clinicians boost patient care.
In fact, Masimo Root, a multimodal patient monitoring and connectivity platform, augmented by iSirona, aids in keeping accurate record of all patient data and presenting it to clinicians in the most suitable ways.
Industry Prospects
Per a report by Fortune Business insights, the global medical device market size was valued at $425.5 billion and is expected to reach $612.7 billion by 2025, at a CAGR of 5.4%. Technological advancement and rising demand for innovative therapies to overcome unmet healthcare needs are driving this market.
Notable Developments
In December 2020, Masimo announced that it is lending support to Renown Health by helping clinicians to address the COVID-19 surge through use of Masimo SafetyNet. Masimo SafetyNet is being utilized to provide care for COVID-19 infected patients to recover in the safety of their homes.
In November 2020, Masimo announced the receipt of CE mark for its Radius VSM, a wearable, tetherless vital signs monitor, and has been released in limited European markets. It offers a wide variety of physiological measurements, including continuous SET pulse oximetry, non-invasive blood pressure, body temperature, respiration rate, and electrocardiography.
Price Performance
Shares of the company have gained 50.3% in a year’s time compared with the industry’s growth of 22.1%.
Zacks Rank and Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space include Cantel medical Corp. , Hologic, Inc. (HOLX - Free Report) and Delcath Systems, Inc. (DCTH - Free Report) . While Cantel Medical and Hologic sport a Zacks Rank #1 (Strong Buy), Delcath Systems carries a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Cantel Medical has an estimated long-term earnings growth rate of 19%.
Hologic has an estimated long-term earnings growth rate of 17%.
Delcath Systems has a projected long-term earnings growth rate of 69%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>